Corporate Banner
Satellite Banner
Genomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oklahoma Acquires New Imaging Technology

Published: Thursday, September 05, 2013
Last Updated: Thursday, September 05, 2013
Bookmark and Share
Protea Biosciences have announced that the University of Oklahoma’s Institute for Natural Products Applications and Research Technologies (INPART) has acquired the LAESI DP1000 biomolecular imaging system.

INPART is directed by Robert Cichewicz, PhD., associate professor in the Department of Chemistry and Biochemistry. The instrument will be used for the Institute’s natural products-based drug discovery operations. 

Cichewicz will be using this new instrument to characterize newly discovered compounds produced by fungi and other microbes, in an effort to develop new treatments for life-threatening infections. LAESI (short for Laser Ablation Electrospray Ionization) is designed to rapidly generate imaging profiles of the biomolecules present in cells and to analyze tissue sections identical to those used in pathology. The LAESI DP-1000 is intended to allow the direct identification of biomolecules in living cells and bacterial colonies, with analysis completed in seconds to minutes. Thus, molecular changes that occur in cells over time can be identified and tracked. 

Cichewicz said, “This instrument is designed to allow us to examine the changes that occur in fungal and bacterial colonies such as their production of secondary metabolites, permitting us to identify and characterize new candidate antimicrobial compounds.” 

Cichewicz’s laboratory studies microbial natural products, which are the unique compounds produced by fungi and bacteria. These compounds play important roles in helping microorganisms adapt to their environment, and they exhibit a diverse array of novel structures. The Cichewicz Laboratory focuses on using secondary metabolites from fungi and bacteria for the treatment of human diseases such as life-threatening infections and cancer. 

The LAESI DP1000, developed by Protea Biosciences, was selected by an independent judging panel and the editors of R&D Magazine to receive a prestigious 2012 R&D 100 Award, as one of the 100 most technologically significant products introduced in the past year. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Protea Announces License Agreement with Yale
Company has announced an exclusive license agreement with Yale for new technology for detecting malignant melanoma skin cancer.
Tuesday, April 26, 2016
Protea, MSK, Dana-Farber Enter Collaborative Research Agreement
Protea's LAESI technology to be used to profile cancer cells to improve diagnosis and treatment selection
Wednesday, April 30, 2014
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Discovered Through ‘Big Data’ Analysis
Researchers at the SBP have identified over 100 new genetic regions that affect the immune response to cancer.
New Therapeutic Targets For Small Cell Lung Cancer Identified
Researchers at UTSW Medical Center have identified a protein termed ASCL1 that is essential to the development of small cell lung cancer and that, when deleted in the lungs of mice, prevents the cancer from forming.
Deciphering Inactive X Chromosomes
Untangling the Barr body of inactive X chromosomes valuable for understanding chromosome structure and gene expression.
Micro Disease-Detecting Senor Created
Researchers at McMaster University have created a microscopic disease-detecting sensor that can turn on to detect trace amounts of substances.
Liquid Biopsies Treating Ovarian Cancer
Researchers have discovered a promising monitor and treat recurrence of ovarian cancer. Detecting cancer long before tumours reappear.
Uncovering a New Principle in Chemotherapy Resistance in Breast Cancer
The NIH study has revealed an entirely unexpected process for acquiring drug resistance that bypasses the need to re-establish DNA damage repair in breast cancers that have mutant BRCA1 or BRCA2 genes.
Understanding Treatment Resistant Melanoma
Researchers have determined how advanced melanoma becomes resistant; a development toward developing treatments.
Investigating ‘Black Box’ of Human Genetics
Investigations into inactive X chromosomes have shown unusual DNA repeat elements are essential for maintaining 3D structure.
Liquid Biopsies: DNA Size Matters
Study finds circulating tumour DNA can be distinguished from healthy DNA through fragment size identification.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!